Top Story

Obinutuzumab, bendamustine significantly extend PFS in relapsed non-Hodgkin's lymphoma

May 30, 2015

Read the Perspective from Stefan Barta, MD

non-Hodgkin’s lymphoma

CHICAGO – The addition of the monoclonal antibody obinutuzumab to standard bendamustine chemotherapy significantly delayed the progression of relapsed indolent non-Hodgkin’s lymphoma, according to the results of an open-label phase 3 study presented at the ASCO Annual Meeting.

Meeting News CoveragePerspective

Adjuvant chemotherapy improves survival for men with high-risk, localized prostate cancer

May 30, 2015
CHICAGO — The addition of docetaxel chemotherapy to standard hormone and radiation therapy reduced the risk for death in men with high-risk, localized prostate…
Ruben A. Mesa, MD Meeting News CoveragePerspective

Pacritinib improves symptom control, reduces spleen volume in patients with myelofibrosis

May 30, 2015
CHICAGO — Pacritinib more effectively induced sustained spleen volume reduction and symptom control in patients with myelofibrosis compared with best available…
Meeting News CoveragePerspective

Ibrutinib combination confers significant benefit in relapsed CLL

May 30, 2015
CHICAGO – The addition of ibrutinib to bendamustine and rituximab conferred an 80% reduction in the risk for progression or death in patients with previously…
Saad Usmani, MD Meeting News Coverage

Daratumumab appears safe, effective in heavily pretreated multiple myeloma

May 30, 2015
CHICAGO – The monoclonal antibody daratumumab yielded durable single-agent activity in patients with heavily treated multiple myeloma, according to the results of…
More News Headlines »
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
VIDEO: Updates in prostate cancer treatment options

VIDEO: Updates in prostate cancer treatment options

May 5, 2015
Robert S. DiPaola, MD, director of Rutgers Cancer Institute of New Jersey, discusses various forms of prostate cancer…
More »
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »